CCL2 and cancer: As the TAM phenotype plays a vital role in the tumor microenvironment, the inhibitory effect of Luteolin on the monocyte recruitment and migration of cancer cells via suppression of the TAM-secreted CCL2 was suggested as a novel therapeutic strategy for cancer [61].